Hormonal and metabolic changes because of postmenopause increase body weight, central abdominal fat, alter lipid profile and insulin resistance, those factors increase the risk up to 60% to develop metabolic syndrome, diabetes and cardiovascular diseases. Because there is no efficient antioxidant therapy in postmenopausal women, this study proposes a therapy with resveratrol and vitamin C to increase the total antioxidant capacity; as well as to decrease insulin resistance and in consequence decreased the risk of diabetes, metabolic syndrome and cardiovascular disease
Currently, there are not studies that demonstrate an efficient antioxidant therapy in postmenopausal women, to increase the total antioxidant capacity and to decrease insulin resistance and biochemical parameters of cardio-metabolic risk. Therefore, the aim of this study is to evaluate the effect of the co-administration of resveratrol and vitamin C on insulin resistance and antioxidant capacity by a double-blind randomized clinical trial. A population of 270 postmenopausal women will be studied, stratified into 3 groups: Group 1: Three-month administration of vitamin C 500 mg daily + placebo Group 2: Three-month administration of resveratrol 500 mg daily + placebo Group 3: Three months administration of vitamin C 500 mg daily and resveratrol 500 mg daily as antioxidant therapy. All participants will be monitored monthly for a period of 3 months: glucose, insulin, uric acid, Homeostatic Model Assessment (HOMA), total cholesterol (TC), triglycerides (TGC), High density lipoproteins-cholesterol (HDL- C), low density lipoproteins-cholesterol (LDL), blood pressure, body mass index (BMI). The antioxidant efficiency in erythrocytes by the quantification of antioxidant enzymes (superoxide dismutase, catalase, glutathione reductase and glutathione peroxidase), as well as total antioxidant capacity in plasma. In order to corroborate the oxidative damage, the product of the lipoperoxidation malondialdehyde and the carbonylation of proteins will be evaluated by spectrophotometric techniques before and three months after the intervention.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
45
Adminstration of vitamin C (500 mg / day/orally) + placebo (same presentation like resveratrol)
Adminstration of resveratrol (500 mg / day/orally) + placebo (same presentation like vitamin C)
Adminstration of resveratrol (500 mg / day/orally) + vitamin C 500 mg/day/orally)
Instituto Nacional de Perinatología Isidro Espinosa de los Reyes
Mexico City, Mexico
Insulin resistance
Insulin resistance measured by HOMA (Homeostatic Model Assessment)
Time frame: HOMA at 3 months after starting the intervention in each group
Superoxide dismutase activity
Enzymatic activity measured by spectrophotometry
Time frame: three months after starting the intervention
Catalase activity
Enzymatic activity measured by spectrophotometry
Time frame: three months after starting the intervention
Glutathione peroxidase activity
Enzymatic activity measured by spectrophotometry
Time frame: three months after starting the intervention
Glutathione reductase activity
Enzymatic activity measured by spectrophotometry
Time frame: three months after starting the intervention
Malondialdehyde
Enzymatic activity measured by spectrophotometry
Time frame: three months after starting the intervention
Carbonylation of proteins
Marker of oxidative stress measured by spectrophotometry
Time frame: three months after starting the intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.